Kakos Christos Dimitrios, Ziogas Ioannis A, Tsoulfas Georgios
Surgery Working Group, Society of Junior Doctors, Athens 15123, Greece.
Department of Transplantation Surgery, Aristotle University School of Medicine, Thessaloniki 54622, Greece.
World J Transplant. 2022 May 18;12(5):88-99. doi: 10.5500/wjt.v12.i5.88.
Children infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seem to have a better prognosis than adults. Nevertheless, pediatric solid organ transplantation (SOT) has been significantly affected by the unprecedented coronavirus disease 2019 (COVID-19) pandemic during the pre-, peri-, and post-transplant period. Undoubtedly, immunosuppression constitutes a real challenge for transplant clinicians as increased immunosuppression may prolong disease recovery, while its decrease can contribute to more severe symptoms. To date, most pediatric SOT recipients infected by SARS-CoV-2 experience mild disease with only scarce reports of life-threatening complications. As a consequence, after an initial drop during the early phase of the pandemic, pediatric SOTs are now performed with the same frequency as during the pre-pandemic period. This review summarizes the currently available evidence regarding pediatric SOT during the COVID-19 pandemic.
感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的儿童似乎比成人预后更好。然而,小儿实体器官移植(SOT)在移植前、移植中和移植后期间受到了前所未有的2019冠状病毒病(COVID-19)大流行的显著影响。毫无疑问,免疫抑制对移植临床医生构成了真正的挑战,因为免疫抑制增加可能会延长疾病恢复时间,而免疫抑制降低则可能导致症状更严重。迄今为止,大多数感染SARS-CoV-2的小儿SOT受者病情较轻,仅有少量危及生命并发症的报告。因此,在大流行早期出现初始下降之后,现在小儿SOT的实施频率与大流行前时期相同。本综述总结了关于COVID-19大流行期间小儿SOT的现有证据。